ESC 365 - Wild type transthyretin cardiac amyloidosis (wtATTR) and heart failure with reduced ejection fraction (HFrEF): can angiotensin receptor/neprilysin inhibitors be a therapeutic option?

HFA Premium Access

Wild type transthyretin cardiac amyloidosis (wtATTR) and heart failure with reduced ejection fraction (HFrEF): can angiotensin receptor/neprilysin inhibitors be a therapeutic option?

Session: Myocardial disease 2

Topic: Myocardial Disease

Speaker: Doctor B. Fowler (Monza, IT)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Bianca Fowler

University of Milan-Bicocca, Monza (Italy)

1 presentation

0 follower

3 more presentations in this session

New clues to the diagnosis of dynamic obstructive gradiente in hypertrophic cardiomyopathy. The power of ergoespirometry

Speaker: Doctor A. Diaz Exposito (Malaga, ES)

Eosinophilic myocarditis with extensive late gadolinium enhancement: how do we treat it?

Speaker: Doctor S. Vila-Sanjuan (Barcelona, ES)

Swollen heart after Covid-19: temporary left ventricular wall thickening in acute intermittent porphyria

Speaker: Doctor P. Suwalski (Berlin, DE)

Access the full session

Myocardial disease 2

Speakers: Doctor B. Fowler, Doctor A. Diaz Exposito, Doctor S. Vila-Sanjuan, Doctor P. Suwalski

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources